Irish Gene Therapy for Blindness is Acquired by US Leader in the Field

08/03/2016 - 3 minutes

Spark Therapeutics (US) has paid over €13.5M for Genable Technologies (Ireland) and its gene therapy for a degenerative eye disease which progresses to blindness.

spark_therapeutics_genable_technologies_gene_thearpy_inherited_retinal_dystrophies_rhonova_suppression_replacementSpark Therapeutics is one of the players in the re-emerging field of Gene Therapy (which is already establishing records like the most expensive drug). It focuses on debilitating genetic diseases, like inherited retinal dystrophies (IRDs), neurodegenerative and blood disorders.

It will now add a new candidate to its IRD pipeline, RhoNova, which was in preclinical development with the collaboration with Genable Technologies since 2014.

Spark has now decided to go all the way and buy the Irish Biopharma for $6M cash and $9.15M worth of Spark’s stocks (265,000 shares), amounting to about €13.76M.

Genable has an innovative approach to the treatment of autosomal dominant diseases. For these types of genetic diseases, having only one copy of a mutated gene can lead to developing symptoms (even if the other copy is healthy).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!